Literature DB >> 17885043

Sonography of benign conditions of the anal canal: an update.

Francesca Berton1, Giada Gola, Stephanie R Wilson.   

Abstract

OBJECTIVE: The objective of this article is to describe our experience with sonography for the study of benign conditions of the anal canal and perianal soft tissues.
CONCLUSION: Assessment of the anal sphincters in patients with fecal incontinence and documentation of perianal inflammatory masses and tracts in those with perianal inflammatory disease are the major indications for imaging the anal canal. We augment traditional transanal sonography with transperineal scanning in both sexes and transvaginal scanning in women to better show the anal canal in its quiet state to allow an accurate assessment of the integrity of the anal sphincters and of evidence of acute or chronic inflammatory involvement.

Entities:  

Mesh:

Year:  2007        PMID: 17885043     DOI: 10.2214/AJR.07.2485

Source DB:  PubMed          Journal:  AJR Am J Roentgenol        ISSN: 0361-803X            Impact factor:   3.959


  4 in total

1.  A simplified method for anal ultrasonography: assessment of patient satisfaction and the simplicity of the procedure.

Authors:  D Castellani; E Antonelli; G Sabatino; V Giuliano; A Morelli; G Bassotti
Journal:  Tech Coloproctol       Date:  2008-08-05       Impact factor: 3.781

Review 2.  Imaging in urogynaecology.

Authors:  Alexandros Derpapas; Giuseppe Alessandro Digesu; Ruwan Fernando; Vik Khullar
Journal:  Int Urogynecol J       Date:  2011-05-28       Impact factor: 2.894

3.  Three-dimensional anal endosonography in depicting anal-canal anatomy.

Authors:  A Reginelli; Y Mandato; C Cavaliere; N L Pizza; A Russo; S Cappabianca; L Brunese; A Rotondo; R Grassi
Journal:  Radiol Med       Date:  2012-01-07       Impact factor: 3.469

4.  The immediate effect of vaginal and caesarean delivery on anal sphincter measurements.

Authors:  Deniz Karcaaltincaba; Salim Erkaya; Hatice Isik; Ali Haberal
Journal:  J Int Med Res       Date:  2016-06-28       Impact factor: 1.671

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.